Antibe Therapeutics Approved to Conduct Phase II Trial for ATB-346

Antibe Therapeutics has announced that it has received approval from Health Canada to initiate a Phase 2, double-blind, gastrointestinal endoscopy trial for its lead drug ATB-346.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news